Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
about
The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancerFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyChemotherapy-induced peripheral neurotoxicity: a critical analysisClinical implementation of pharmacogeneticsIrinotecan pharmacogenomicsGlutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with CyclophosphamideA 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia.The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer.A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.Predicting acute and persistent neuropathy associated with oxaliplatin.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSafety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesLeveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerGenetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancerGenetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer.Platinum-induced neurotoxicity and preventive strategies: past, present, and futureAn internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsMethylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancerInformative gene network for chemotherapy-induced peripheral neuropathyChemotherapy-induced neutropenia during adjuvant treatment for cervical cancer patients: development and validation of a prediction model.Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivoGenetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.Chemotherapy-induced peripheral neuropathy: Current status and progress.Pharmacogene regulatory elements: from discovery to applicationsClinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line SettingAnalysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer.A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea.Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis
P2860
Q24603861-254334B0-880E-4B8D-BD03-8C59B384F86DQ26851060-1042978A-7AE0-4A87-B33A-64CDEEC163E3Q27010318-1EED638D-FB6E-4525-9022-37BB5C1467BFQ28072159-A94FC6A6-B144-4D44-809A-5534068FE8EBQ28287024-5C51D8DF-3648-4138-8921-6D0336C2E62AQ28550922-52FC331E-5D20-4A32-9703-C15B4B9B7CEDQ33415092-B8C4A1F5-FC1A-4AB0-B38E-6FACE0A0A50AQ33428367-043DD82A-CADB-4602-BD42-458DAEB1AAF5Q33810014-768D9719-CF57-4D7F-92F3-325100F37B72Q33841734-9A4CB2D5-BB62-491A-A224-84C3CB9F04B7Q34008793-B5ED3615-9E8C-4C76-B326-30107996C081Q34023788-4F967AEC-12FB-4540-B7B7-959DDAB9042DQ34048515-7658C580-9947-4725-AFB7-4652AA47B8F0Q34274096-A6CD936A-62F5-4B1B-92A7-845DBF5B3187Q34452900-2D96B892-F948-4250-9ADB-9C4FF3842F54Q34629650-A6BC292C-1F8D-4670-B708-B70602351150Q34670717-96B08672-C7F3-40AD-ACC1-0BE840AD07D6Q34733071-29341AC3-3064-4A48-9D92-D3EE6646D6BDQ35021702-B70857FD-0D80-4AA0-83B7-B4C214B80D7CQ35109800-D3375792-3A64-4202-82BE-6FFD7E0C1C34Q35146616-8487D12C-FB26-46CF-8B9A-1AA8E002CF3CQ35345734-F484F1DD-1951-4DE1-A3BF-9888370BCDD9Q35603648-32F67E92-001C-481D-9DB4-FB2C5C2AA34EQ35623320-F8C1BD42-8B6F-489B-AE6D-250E1AC663F5Q35742555-C528369A-D855-41C6-9E7A-A54A57FC6946Q35945680-9D489E69-E8BC-441E-895F-608A78851B2CQ36046284-EC347750-E05E-4525-8475-0FEC277941EBQ36051757-FDBC3702-CD42-4559-878F-3D18A076839DQ36070191-E7FE3E7A-568B-4348-8800-49B116DFB307Q36111221-67639099-2930-48D6-9131-D3F78F7736E7Q36219923-D4582127-E1B7-40E4-B1AD-DF4012AD9E13Q36421901-ED7471BC-F198-4623-9663-39DFB2EB6B89Q36424755-A818A3EC-2AC8-4A97-90C5-2807EBA4C053Q36427498-13C09AB1-9C1C-46F0-B9B4-1ED05E96AD84Q36530731-7D2C29A3-F5D7-4487-BA6D-3A7CD2AB6E89Q36630521-831E1067-11F0-414E-AB9E-F64F4AA73EE1Q36746734-8C43601E-670A-4C43-872E-8C1D4308BFEEQ36815039-761760BB-D55A-4C2F-9443-5D2180ECACD3Q37042575-A4841F61-60ED-42C9-A27A-54EFC0DCD584Q37089932-D1D34E10-8098-460D-808D-74544F365F16
P2860
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@ast
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@en
type
label
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@ast
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@en
prefLabel
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@ast
Pharmacogenetic predictors of ...... stinal Intergroup Trial N9741.
@en
P2093
P2860
P356
P1476
Pharmacogenetic predictors of ...... estinal Intergroup Trial N9741
@en
P2093
Axel Grothey
Brian P Findlay
Cristi R King
Erin M Green
Howard L McLeod
Ramesh K Ramanathan
Richard M Goldberg
Roscoe F Morton
Sharon Marsh
Stephen K Williamson
P2860
P304
P356
10.1200/JCO.2009.21.7943
P407
P577
2010-06-07T00:00:00Z